Europe PMC
open access
ONC201/dordaviprone for H3 K27M-mutant tumors: Discovery, mechanisms, therapeutic potential, and future directions
ONC201 (dordaviprone) has recently received accelerated approval for the treatment of recurrent H3 K27M-mutant diffuse midline glioma. Originally identified as TRAIL-inducing compound 10 (TIC10), ONC201 is a first-in-class small molecule distinguished by a unique pharmacologic profile. It promotes a
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors#1032721
- Post-approval Study of NovoTTF-100A in Recurrent GBM Patients#1337233
- LY293111 in Treating Patients With Advanced Solid Tumors#857662
- Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.#895679
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations#892861
Record · ID 1203999
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive